zoledronate
zoledronate is a pharmaceutical drug with 22 clinical trials. Currently 7 active trials ongoing. Historical success rate of 63.6%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
5
Mid Stage
11
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
58.3%
7 of 12 finished
41.7%
5 ended early
7
trials recruiting
22
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)
Zoledronate to Prevent Bone Health Complications in Pediatric Hematopoietic Stem Cell Transplant Survivors
Step-down Therapy After Long-term Osteoporosis Treatment
The Optimal Sequential Therapy After Long Term Denosumab Treatment
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
Clinical Trials (22)
Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)
Zoledronate to Prevent Bone Health Complications in Pediatric Hematopoietic Stem Cell Transplant Survivors
Step-down Therapy After Long-term Osteoporosis Treatment
The Optimal Sequential Therapy After Long Term Denosumab Treatment
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2)
Sequential Therapies After Osteoanabolic Treatment
The Effect of Zoledronate on the Prevention of Pneumonia in Hip Fracture Patients
The Optimised Use of Romozosumab Study
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer
Denosumab vs Zoledronate After Lumbar Fusion
Denosumab vs Zoledronate After Vertebroplasty
Bone Loss Treatment From Adjuvant Zoledronate Efficacy
4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases
Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer
Pre-operative Zoledronate in Triple Negative Breast Cancer
Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3
Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma
S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone
Zoledronate With Atorvastatin in Renal Cell Carcinoma
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 22